SEARCH:   Advanced

Blood, 15 June 2006, Vol. 107, No. 12, pp. 4643-4649. Prepublished online as a Blood First Edition Paper on February 21, 2006; DOI 10.1182/blood-2005-11-4659. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-11-4659v1 107/12/4643    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Arcaini, L. Articles by Iannitto, E. Search for Related Content PubMed PubMed Citation Articles by Arcaini, L. Articles by Iannitto, E. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Splenic marginal zone lymphoma: a prognostic model for clinical use Luca Arcaini, Mario Lazzarino, Nora Colombo, Sara Burcheri, Emanuela Boveri, Marco Paulli, Enrica Morra, Marcello Gambacorta, Sergio Cortelazzo, Alessandra Tucci, Marco Ungari, Achille Ambrosetti, Fabio Menestrina, Lorella Orsucci, Domenico Novero, Alessandro Pulsoni, Maurizio Frezzato, Gianluca Gaidano, Daniele Vallisa, Viviana Minardi, Claudio Tripodo, Vincenzo Callea, Luca Baldini, Francesco Merli, Massimo Federico, Vito Franco, Emilio Iannitto, for the Intergruppo Italiano Linfomi From the Divisions of Hematology and Pathology, IRCCS Policlinico San Matteo, University of Pavia, Pavia; Divisions of Hematology and Pathology, Ospedale Niguarda Ca' Granda, Milano; Division of Hematology, Ospedali Riuniti, Bergamo; Divisions of Hematology and Pathology, Ospedali Civili, Brescia; Departments of Clinical and Experimental Medicine and of Pathology, University of Verona, Verona; Divisions of Hematology and Pathology, Azienda Ospedaliera S. Giovanni Battista, Torino; Department of Hematology, University La Sapienza, Roma; Division of Hematology, Ospedale S. Bortolo, Vicenza; Division of Hematology, Amedeo Avogadro University of Eastern Piedmont, Novara; Division of Medicine and Hematology, Ospedale G. da Saliceto, Piacenza; Divisions of Hematology and Pathology, University of Palermo, Palermo; Bone Marrow Transplant Unit, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria; Department of Hematology, IRCCS Ospedale Maggiore, University of Milano, Milano; Division of Hematology, Ospedale S. Maria Nuova, Reggio Emilia; and Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy. The Integruppo Italiano Linfomi (IIL) carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic factors in 309 patients. The 5-year cause-specific survival (CSS) rate was 76%. In univariate analysis, the parameters predictive of shorter CSS were hemoglobin levels below 12 g/dL (P < .001), albumin levels below 3.5 g/dL (P = .001), International Prognostic Index (IPI) scores of 2 to 3 (P < .001), lactate dehydrogenase (LDH) levels above normal (P < .001), age older than 60 years (P = .01), platelet counts below 100 000/µL (P = .04), HbsAg-positivity (P = .01), and no splenectomy at diagnosis (P = .006). Values that maintained a negative influence on CSS in multivariate analysis were hemoglobin level less than 12 g/dL, LDH level greater than normal, and albumin level less than 3.5 g/dL. Using these 3 variables, we grouped patients into 3 prognostic categories: low-risk group (41%) with no adverse factors, intermediate-risk group (34%) with one adverse factor, and high-risk group (25%) with 2 or 3 adverse factors. The 5-year CSS rate was 88% for the low-risk group, 73% for the intermediate-risk group, and 50% for the high-risk group. The cause-specific mortality rate (x 1000 person-years) was 20 for the low-risk group, 47 for the intermediate-risk group, and 174 for the high-risk group. This latter group accounted for 54% of all lymphoma-related deaths. In conclusion, with the use of readily available factors, this prognostic index may be an effective tool for evaluating the need for treatment and the intensity of therapy in an individual patient. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. KALPADAKIS, G. A. PANGALIS, E. DIMITRIADOU, M. K. ANGELOPOULOU, M. P. SIAKANTARIS, M.-C. KYRTSONIS, M. XIMERIS, T. TZENOU, S. SAHANAS, X. YIAKOUMIS, et al. Mutation Analysis of IgVH Genes in Splenic Marginal Zone Lymphomas: Correlation with Clinical Characteristics and Outcome Anticancer Res, May 1, 2009; 29(5): 1811 - 1816. [Abstract] [Full Text] [PDF] E. Boveri, L. Arcaini, M. Merli, F. Passamonti, S. Rizzi, L. Vanelli, E. Rumi, S. Rattotti, M. Lucioni, C. Picone, et al. Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients Ann. Onc., January 1, 2009; 20(1): 129 - 136. [Abstract] [Full Text] [PDF] J. S. Abramson, M. Chatterji, and A. Rahemtullah Case 39-2008 -- A 51-Year-Old Woman with Splenomegaly and Anemia N. Engl. J. Med., December 18, 2008; 359(25): 2707 - 2718. [Full Text] [PDF] L Arcaini, S Burcheri, A Rossi, M Paulli, R Bruno, F Passamonti, E Brusamolino, A Molteni, A Pulsoni, M. Cox, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT Ann. Onc., February 1, 2007; 18(2): 346 - 350. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020